Study finds big pharma inconsistent with disclosure of clinical trial data
12 November 2015 | By Victoria White
Almost half of all drugs reviewed as part of the study had at least one undisclosed Phase II or III trial...
List view / Grid view
News
Research reveals antibiotic prescriptions are rising in the most deprived areas
12 November 2015 | By Victoria White
The data reveals antibiotic prescribing hotspots and interesting correlations against areas of deprivation. It also shows seasonal variation in antibiotic prescribing...
SEEK’s universal flu vaccine is one step closer
12 November 2015 | By Victoria White
FLU-v is a peptide-based vaccine that stimulates a cytotoxic T lymphocyte and non-neutralising antibody response against influenza. FLU-v may have potential as a cross-protective vaccine for multiple strains of influenza...
Kuros announces second closing of CHF 20 million financing round
12 November 2015 | By Victoria White
The additional financing will allow Kuros to further accelerate its efforts to bring its sealant products to market and to progress its lead orthobiologics product...
Dr Vasant Narasimhan elected a member of the US National Academy of Medicine
11 November 2015 | By Victoria White
The US National Academy of Medicine (NAM) recently announced the election of Dr Vasant “Vas” Narasimhan as a member of the Academy.
Blood cancer drug trial reveals life-changing results
11 November 2015 | By Victoria White
The clinical trial, a first-in-man study, looked at the efficacy of ONO/GS-4059 in the treatment of Chronic Lymphocytic Leukaemia and Non-Hodgkin Lymphoma patients...
GSK announces Phase III results for belimumab in SLE
11 November 2015 | By Victoria White
The results showed that belimumab administered subcutaneously plus standard of care (SoC) demonstrated significantly greater reductions in disease activity compared to placebo plus SoC...
LEO Pharma to acquire global dermatology portfolio from Astellas
11 November 2015 | By Victoria White
The transaction will be the largest in LEO Pharma’s more than 100-year history in terms of incremental turnover...
Hanmi and Janssen sign agreement to develop HM12525A
11 November 2015 | By Victoria White
HM12525A is a novel biologic GLP-1/Glucagon dual receptor agonist to treat diabetes and obesity...
FDA approves Cotellic plus Zelboraf in advanced melanoma
11 November 2015 | By Victoria White
The approval is for the treatment of people with BRAF V600E or V600K mutation-positive unresectable or metastatic melanoma...
Anifrolumab met primary and secondary endpoints in lupus trial
10 November 2015 | By Victoria White
Anifrolumab is a new monoclonal antibody against the type I interferon (IFN) receptor that inhibits the activity of all type I IFNs, which play a central role in lupus...
Lilly’s ixekizumab demonstrates efficacy in psoriatic arthritis
10 November 2015 | By Victoria White
Psoriatic arthritis patients treated with ixekizumab for 24 weeks achieved significant improvements in signs and symptoms of their disease compared to placebo...
Investigational Enbrel biosimilar CHS-0214 meets primary endpoints
10 November 2015 | By Victoria White
CHS-0214 met its primary endpoints in a Phase 3 study in patients with moderate-to-severe chronic plaque psoriasis...
SMC accepts Keytruda as a treatment option for advanced melanoma
10 November 2015 | By Victoria White
The SMC also announced positive recommendations for Roche’s Avastin (bevacizumab) and Daiichi Sankyo’s Lixiana (edoxaban)...
Study demonstrates clinical equivalence of ABP 501 with adalimumab
10 November 2015 | By Victoria White
ABP 501 is being developed as a biosimilar candidate to adalimumab, an anti-TNF-α monoclonal antibody, which is approved in many countries for the treatment of inflammatory diseases...
